gi-102
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 30, 2023 (NCT05824975)
Timeline
Indications
Mechanism of action
- T-lymphocyte activation antigen CD80MODULATOR
CD80 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07301268 | Phase 2 | Dec 29, 2025 | Mayo Clinic |
| NCT05824975 | Phase 1/Phase 2 (Phase 2) | May 30, 2023 | GI Innovation, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GI Innovation, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1